Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2010 December;62(6) > Minerva Ginecologica 2010 December;62(6):509-13





A Journal on Obstetrics and Gynecology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index




Minerva Ginecologica 2010 December;62(6):509-13

language: Italian

Short-term effect of an estroprogestin containing ethinyl-estradiol 20 mcg + drospi-renone 3 mg in 24+4 regimen at hormonal and cutaneous level in ovarian hyperandrogenism

Lello S. 1, Pacifico V. 2, Primavera G. 2, Guardianelli F. 1, Sorge R. 3, Paoletti A.M. 4, Melis G.B. 4, Raskovic D. 2, Colonna L. 2

1 Servizio di Ginecologia Endocrinologica e Fisiopatologia della Menopausa;
IRCCS-Istituto Dermopatico dell’Immacolata Roma, Italia;
2 Servizio di Dermocosmetologia e Fisiopatologia Cutanea, IRCCS-Istituto Dermopatico dell’Immacolata Roma, Italia;
3 Laboratorio di Biometria, Università di Roma Tor Vergata, Roma, Italia;
4 Clinica Ostetrica e Ginecologica, Università di Cagliari, Cagliari, Italia


AIM: evaluate the efficacy of an estroprogestin EP containing 20 mcg ethinilestradiol (EE) and 3 mg drospirenone (DRSP) in the treatment of hyperandrogenism.
METHODS: In this study, twenty hyperandrogenic patients were treated with an EP containing EE 20 mcg and DRSP 3 mg in 24+4 regimen for three months. Skin evaluation was performed both quantitatively and qualitatively.
RESULTS AND CONCLUSION: This EP combination showed, after a short-term treatment (three months) to decrease significantly seborrhea, acne, and circulating androgens (testosterone, deidroepiandrosterone sulphate, and androstenedione), while increased sex hormone binding globulin levels. Moreover, this EE 20 mcg/DRSP 3mg EP combination changed some parameters of skin quality, increasing corneometry (a parameter related to skin hydration), and reduced trans epidermal water loss (TEWL, a parameter related to skin evaporation), and erythema (a parameter related to skin inflammation). These results could be taken into account in individualizing the treatment of hyperandrogenic patients.

top of page

Publication History

Cite this article as

Corresponding author e-mail